What is the recovery time after stem cell therapy for ALS (Motor Neurone Disease)?
Recovery and risk depend on the exact product and route, particularly when lumbar puncture, intrathecal administration, surgery or immunosuppression is involved. Trial documents should describe observation, neurological and respiratory monitoring, infection and emergency arrangements, and follow-up. Patients must continue neurologist-directed ALS care; no medicine or respiratory support should be changed because of an experimental procedure without specialist agreement.
What the evidence shows for ALS (Motor Neurone Disease)
Human ALS cell-therapy studies are generally early-phase and heterogeneous, with different products, routes, populations and endpoints. Safety observations and exploratory biomarker changes do not establish slower functional decline or longer survival. No completed pivotal trial has established a stem-cell product as effective standard ALS treatment. No pooled response rate is published here because the studies are too heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
Am I a candidate? → · ALS (Motor Neurone Disease): full overview → · ALS (Motor Neurone Disease) cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- ALS (Motor Neurone Disease): cell-therapy evidence and registered trials
- How much does stem cell therapy for ALS (Motor Neurone Disease) cost? (2026)
- ALS (Motor Neurone Disease) stem cell therapy — your questions answered (2026)
- ALS (Motor Neurone Disease): cell-therapy evidence by therapy class
- MSC vs HSCT for ALS (Motor Neurone Disease): what the registries show